CCBPA Advisory Committee

Dr. Min Wang

Dr. Wang received her Medical degree and Master of Science degree from the Third PRC Medical University in China.  She has completed her Ph.D. from the University of Toronto, Canada in 1994. After a short post-doctoral fellowship with a Canadian Medical Research Council postdoctoral fellowship, she accepted an industry position at Canadian Dimethied Pharmaceutical Research Incorporation managing anti-arthritis drug development.  In 1999, Dr. Wang joined the Parke-Davis pharmaceutical division of Warner Lambert Corp. as a medical scientist and project manager in cardiovascular clinical research and was responsible for the international development of Lipitor and other cardiovascular drugs.  Dr. Wang accepted the position of Associate Director of Cardiovascular and Metabolic Diseases at Bayer Pharmaceutical Inc. in mid 2000. In this role, she manages phase I to IV clinical trials in the global and North America settings, participates in global and local regulatory submissions, and works closely with the teams of Scientific Affairs, Marketing and Sales force. Her focuses in the drug development are in the areas of cardiovascular, diabetes, anti-thrombosis and oncology.  Recently Dr. Wang is promoted as Director and Global Medical Expert of Bayer Global Clinical Development in Asia Pacific and relocated to Beijing of China. 

Dr. Dongxu Qiu

邱东旭,1982年毕业于沈阳药科大学并获学士学位。1987年获得北京大学医学部药物化学博士学位。2000年获得Richard Ivey School of Business, The University of Western Ontario的工商管理硕士学位。1989-1991年获洪堡基金资助赴德国进行博士后研究。1991-1992年在蒙特利尔大学HANESSIAN教授的实验室做博士后研究。1993年加入BIOMIRA公司，先后任科学家，资深科学家，项目经理，以及部门经理，主要从事新药研究与开发，领导一组科学家参与了BIOMIRA两个关键产品(Theratope and BLP-25) 的研制。1999年加入ALTAREX公司，任部门主任，主要负责ALTAREX的两个抗体产品(OverRexTM和BrevaRexTM) 的生产及生产路线的改进。2000年加入ARIUS RESEARCH公司，任营运主管，负责公司的五个部门运营。2002年加入MDS CAPITAL，任亚洲区总裁，负责MDS CAPITAL在中国，香港，台湾，新加坡及韩国的业务，主要从事基金的募集，生物医药公司的投资，以及生物医药技术的转让，为MDS CAPITAL在台湾融到三千万美元并成功地帮助三家美国公司进军亚洲。2005年至今回国主要从事生物医药领域的顾问工作，先后任加拿大WEX医药公司营运副总经理，负责其公司的亚洲事物并兼任香港分公司和中国分公司的总经理；北京昭衍新药研发中心的总裁，负责该公司的国际业务开发；上海吉玛制药技术有限公司常务副总经理,负责该公司的融资和市场开发工作,并为该公司融到近两百五十万美元；美国PHARMALEGACY公司高级顾问，帮助公司融资八百五十万美元；美国沪亚生物技术公司的中国总经理，全面负责沪亚在中国的业务，为沪亚生物技术公司在中国找到近200多个新化合物。目前任美国CHINABIO LLC公司中国总经理，全面负责该公司在中国的的顾问业务。2003以来应邀在19个国际会议上演讲或参加公开讨论。

Dr. Jianguo Wang

王建国，曾任加拿大Apotex 药物及检测方法开发部经理。 毕业于山东大学。85年到加拿大蒙特利尔 (Montreal) 大学生物化学系及化学系深造。在著名有机化学家 Hanessian 教授指导下，发表多篇抗癌药物的全合成及生物专一活性方面的论文。获博士学位后，到多伦多 (Toronto) 大学化学系进行酶抑制剂的合成及活性研究。94年加入加拿大最大的制药公司 Apotex, 先后在研究和开发部，原料合成及专利申请，药物开发及分析检测部门进行研究和管理工作。多年来，参与过数十种药物产品的开发，检测分析方法确立以及管理。2000-2001年曾在德国默克 (Merck) 在加拿大的制药分公司Genpharm任原料进口及质量评定主任。目前在中国创办公司。

Ms. Jianying Wang

Ms. Wang, born in China, received BSc in Chemical Engineering from South China University of Technology and MBA from Edinburgh Business School in UK. She worked in environmental protection field in China and Canada. Since 1990, she has been working at Novopharm Ltd., a subsidiary of Teva Pharmaceutical Industries Ltd (the largest generic company in the world), as senior biochemist, RA associate, team leader and manager of Regulatory Affairs, and she is now responsible for US submission.

Ms. Wenli Zhao

Ms. Zhao first started her experience in biotechnology at the Biotechnology Program, Beijing University. After achieved her honored Bachelor degree, she came to Canada to  continue with her education at the Master of Biotechnology program at the University of Toronto. In year 2006, she moved on to complete her Master in Business Administration (MBA) degree at McMaster University. In between her studies, Ms. Zhao attempted to get diversified experiences in biotechnology industry. She conducted molecular biology research at the University  of Toronto, worked in drug development department at NPS     pharmaceuticals, had experience in regulatory affairs with GlaxoSmithKline, learned drug pricing and reimbursement issues at Eli Lilly Canada and performed policy research with BIOTECanada.